
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics is an attractive investment opportunity, with a large potential market of millions of patients facing the risk of developing esophageal cancer. The company's EsoGuard and EsoCheck products have shown promising results in detecting Barrett's Esophagus and Esophageal Adenocarcinoma, and the positive sentiment from Medicare's Contractor Advisory Committee meeting in September 2025 indicates potential future coverage and reimbursement. Although there is risk associated with the company's commercialization efforts and competitive landscape, the potential for high rewards and the company's progress on securing Medicare coverage make for a positive outlook.
Bears say
Lucid Diagnostics is a commercial-stage medical diagnostics company, focusing on patients with gastroesophageal reflux disease (GERD) through their EsoCheck and EsoGuard products. While the market potential for these products is large, the long commercialization and growth challenges ahead present risky prospects for investors. Additionally, the high revenue CAGR and EV/sales multiple in the bull case scenario may not be achievable.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares